Tamiflu Population Differences Could Be Studied In U.K, HMO Databases
Executive Summary
Population differences with regard to serious adverse events in patients receiving Roche's antiviral Tamiflu could be explored using large databases, such as the U.K. General Practitioner Research Database and the UnitedHealthcare database, FDA's Pediatric Advisory Committee suggested on Nov. 18
You may also be interested in...
Tamiflu Data Reassures FDA Panel; Label Changes To Stress Flu’s Role In AEs
Despite the fact that safety questions linked to Roche's influenza drug Tamiflu (oseltamivir) are still lingering, the data on the drug presented by the firm to FDA's Pediatric Advisory Committee is proof that the "system worked," panelists said at the Nov. 27 meeting
Tamiflu Data Reassures FDA Panel; Label Changes To Stress Flu’s Role In AEs
Despite the fact that safety questions linked to Roche's influenza drug Tamiflu (oseltamivir) are still lingering, the data on the drug presented by the firm to FDA's Pediatric Advisory Committee is proof that the "system worked," panelists said at the Nov. 27 meeting
Avian Flu Plan From Administration Places Vaccines First, Antivirals Second
The Bush Administration's pandemic flu preparedness plans call for a dramatic expansion in the stockpiling of antivirals, an increase expected to be largely paid for by the states